摘要
目的评价比卡鲁胺联合戈舍瑞林间断性治疗对晚期前列腺癌的治疗效果。方法选择2014年6月至2016年1月在我院确诊并治疗的106例晚期前列腺癌患者作为研究对象,随机分为试验组(53例)和对照组(53例),试验组患者应用比卡鲁胺联合戈舍瑞林进行间断性治疗,对照组持续性给药,两组用法用量相同。随访收集并比较两组患者的前列腺特异抗原(PSA)、游离前列腺特异抗原(f-PSA)、排尿梗阻症、骨转移情况及不良反应发生情况。结果治疗3、6、12个月后,两组的血清PSA、f-PSA水平降低(P <0. 05),排尿梗阻症、骨转移例数减少(P <0. 05),但两组上述指标比较差异无统计学意义(P> 0. 05);试验组性功能障碍(39. 6%vs. 64. 2%,P=0. 011)及潮热(13. 2%vs. 30. 2%,P=0. 034)的发生率低于对照组。结论比卡鲁胺联合戈舍瑞林间断性治疗对晚期前列腺癌的治疗效果与持续性治疗相当,且安全性较高。
Objective To investigate the clinical effect of intermittent treatment of icalutamide combined with goserelin for advanced prostate cancer.Methods Totally106prostate cancer patients treated in our hospital from June2014to January2016were randomized into experiment group(n=53)and control group(n=53).Patients in experiment group and control group were given intermittent and continuous treatment of icalutamide combined with goserelin,respectively.Both groups had the same dose and administration.The levels of PSA and F-PSA between the two groups were compared,and the situation of urinary obstruction,bone metastasis and adverse reaction were observed.Results After3,6and12months of treatment,the levels of PSA and f-PSA of patients and the number of patients with urinary obstruction and bone metastasis were decreased(P<0.05),but there was no significant difference between the two groups(P>0.05).The rates of sexual dysfunction(39.6%vs.64.2%=0.011)and fever(13.2%vs.30.2%,P=0.034)in experiment group were lower than those in control group.Conclusion The clinical efficacy of intermittent and continuous treatments of icalutamide combined with goserelin is similar,and the intermittent treatment has higher safety.
作者
李露霜
臧志军
黄崇梅
张艳丽
许婷
张颖
LI Lu shuang;ZANG Zhi-jun;HUANG Cong-mei;ZHANG Yan-li;XU Ting;ZHANG Ying(Department of Urology,the People's Hospital of Longhua District,Shenzhen 518109 ,China;Third Hospital of Zhongshan University,Guangzhou 510620,China)
出处
《实用药物与临床》
CAS
2018年第12期1353-1355,共3页
Practical Pharmacy and Clinical Remedies
基金
广东省自然科学基金(2016A030310142)
关键词
比卡鲁胺
戈舍瑞林
间断性治疗
前列腺癌
Icalutamide
Goserelin
Intermittent treatment
Prostate cancer
作者简介
通信作者:张颖
